IEX — IDEX Corporation
$220.84
Target: $237.71 (+7.6%)
P/E Ratio
32.3
P/E Forward
25.2
Dividend
1.3%
Market Cap
$16.3B
EPS
$6.76
Consensus
Buy
What they do
IDEX Corporation (NYSE: IEX) is a niche industrial conglomerate. It doesn't make one famous product: it owns dozens of small companies that build critical — often invisible — parts for industry, medicine and safety. The idea is simple and powerful: buy the leader of a very specific corner of the market, improve it, and use the cash it generates to buy the next one. That's called an 'industrial compounder'.
The 3 businesses (segments):
- Fluid & Metering Technologies (FMT) — precision fluid pumps, flow meters, valves and injectors. They move and measure liquids and chemicals with precision in water, energy, agriculture, chemicals and food. It's the most 'classic', industrial business.
- Health & Science Technologies (HST) — the fastest-growing business. It makes precision fluidics and optics: the parts that move microscopic droplets of liquid inside medical diagnostic, lab analysis and scientific instrument machines. This is where the Mott Corporation acquisition landed (sintered porous metal filtration, ~$1 billion in 2024). In Q1 2026 this segment grew +17%.
- Fire & Safety / Diversified Products (FSDP) — firefighting and rescue equipment: pumps for fire trucks and the hydraulic rescue tools (the 'jaws of life' that cut a car open to free an injured person), plus dispensing and clamping equipment.
Why the model works: each part IDEX makes is small within the total cost of its customer's machine, but critical — if the precision pump or the fluidics system fails, the whole machine is useless. That gives it pricing power, high margins and customers who don't switch suppliers lightly. With that cash, IDEX buys more businesses like these (disciplined 'bolt-on' M&A).
Leadership: CEO Eric Ashleman (in the role since December 2020, a company veteran). Headquartered in Northbrook, Illinois. ~9,000 employees worldwide.
Dividend (growing): ~$0.73 per share per quarter (raised in 2026; declared June 17, payable July 24) = ~$2.92 a year = ~1.3% at today's price. It has raised it 16 years in a row and paid it since 1995. Not a high dividend, but the kind that goes up like clockwork.
2026 context (what changed since our first purchase in April): a better-than-expected Q1 2026 — revenue $886.9 million (+9%, +5% organic), adjusted EPS $2.00 (+14%), record orders of $988.3 million (+13%) and adjusted EBITDA of $230.4 million (26.0% margin). The company raised its full-year organic growth target from 1-2% to 3-4% and its adjusted EPS guidance to $8.35-$8.55 per share.
Why we like it
IEX at $220.84 is reinforcing a position we already held since April (~$197.85): it's not a new idea, it's doubling down on a quality business whose thesis got stronger. Specific reasons:
- The thesis was confirmed, that's why we're reinforcing: when we bought in April, we were betting on a high-margin industrial compounder in the middle of a cyclical recovery. Since then it reported a better-than-expected Q1 2026 (adjusted EPS $2.00 vs ~$1.78 expected), record orders of $988.3 million (+13%) and raised its full-year growth target from 1-2% to 3-4%. The recovery is real, not a hope — which is why we paid ~12% more than in April without hesitation.
- The compounder model: IDEX doesn't depend on a trendy product; it owns dozens of small niche leaders, generates lots of cash and reinvests it buying more (Mott, ~$1 billion, is the big recent example). It's a disciplined, decades-proven acquisition machine.
- Small but critical parts = high margins: each IDEX component is cheap within the customer's machine but indispensable; that gives it pricing power and a ~26% EBITDA margin few industrials reach.
- The dividend that rises like clockwork: 16 straight years of increases, paid since 1995 — the sign of a company that generates cash to spare and treats shareholders well, even if the yield (~1.3%) is modest.
- Wall Street backs it: 'Buy' consensus (57% say 'Strong Buy'), average target of ~$238 across 15 analysts. Honesty: the average upside is moderate (~+8%) and the stock isn't cheap (~32x trailing earnings) — here you're not buying a discount, you're buying quality that compounds over time.
Key Risk
Risks:
- Premium valuation — the #1: IDEX is rarely cheap and it isn't today: ~32x trailing earnings and ~25x forward, with an average target (~$238) barely ~8% above today's price. It's an excellent business at a fair price, not a bargain — at these multiples, a stumble gets punished fast.
- Industrial cyclicality: much of its sales depend on factories, power plants, agriculture and industrial customers continuing to invest; when the economy slows, those orders get postponed and IDEX's sales fall (it lived this in 2023-2024, when growth flattened before this recovery).
- Acquisition integration risk: the whole model depends on buying well and digesting well; if it overpays for a business (Mott came at ~19x EBITDA) or the integration fails, the 'compounding' breaks and growth stalls.
- Exposure to many different end markets: IDEX touches dozens of industries (water, health, semiconductors, firefighting, energy); that diversification protects, but it also means there's always some weak segment dragging on the rest — full-year organic growth is only 3-4%.
- Dependence on cash to grow: if cash goes to acquisition debt or rates rise, there's less fuel for the M&A engine that sustains the thesis.
- It's not an income dividend: anyone looking for high income won't find it here (~1.3%); if growth disappoints, there's no generous yield to compensate the wait.
This is educational and informational content, not financial advice. Always consult a qualified financial advisor before making investment decisions.
Vectorial Data picked IEX on 2026-04-08 at $220.84.
Full Research
IDEX Corporation (IEX) — Research Completo (RECOMPRA)
Precio: $220.84 | P/E TTM: ~32.3x | P/E fwd: ~25.2x | Div Yield: ~1.3% | Market Cap: ~$16.3 mil millones USD
Recompra: IDEX ya estaba en el portafolio desde abril de 2026 (~$197.85). Hoy la reforzamos a $220.84 (~+12%) porque la tesis se confirmó con el Q1 2026 y la subida de guía.
¿Qué es IDEX?
Un conglomerado industrial de nicho ('compounder industrial'): en vez de un producto estrella, es dueña de decenas de pequeñas empresas que lideran rincones muy específicos de la industria. Compra el líder de un nicho, lo mejora, y reinvierte el efectivo que genera comprando el siguiente. Sede en Northbrook, Illinois. ~9,000 empleados. CEO: Eric Ashleman (desde diciembre de 2020).
Los 3 negocios (segmentos)
| Segmento | Qué es |
|---|---|
| Fluid & Metering Technologies (FMT) | Bombas de precisión, medidores de flujo, válvulas e inyectores para agua, energía, agricultura, químicos y alimentos |
| Health & Science Technologies (HST) | Fluídica y óptica de precisión para diagnóstico médico, análisis de laboratorio e instrumentos científicos (incluye Mott). En Q1 2026 creció +17% |
| Fire & Safety / Diversified Products (FSDP) | Bombas para camiones de bomberos, herramientas hidráulicas de rescate ('quijadas de la vida'), dispensado y sujeción |
Último trimestre (Q1 2026)
| Métrica | Q1 2026 |
|---|---|
| Ventas netas | $886.9 millones (+9% total, +5% orgánico) |
| Pedidos | Récord: $988.3 millones (+13% reportado, +10% orgánico) |
| Utilidad neta (GAAP) | $120.0 millones |
| EPS diluido GAAP | $1.61 (desde $1.26 un año antes) |
| EPS ajustado | $2.00 (+14%) — arriba del ~$1.78 esperado |
| EBITDA ajustado | $230.4 millones (margen 26.0%) |
| Segmento estrella | Health & Science Technologies +17% |
Guía FY2026 (subida tras el Q1)
| Métrica | Guía |
|---|---|
| Crecimiento orgánico | 3%-4% (subida desde 1%-2%) |
| EPS ajustado | $8.35-$8.55 |
| Margen EBITDA ajustado | 26.5%-27.0% |
Qué cambió desde nuestra primera compra (abril 2026, ~$197.85)
- Q1 2026 batió expectativas (utilidad ajustada $2.00 vs ~$1.78 esperado).
- Pedidos récord de $988.3 millones (+13%) — la mejor señal de que la recuperación del ciclo es real.
- Subió la guía de crecimiento orgánico del año de 1-2% a 3-4%.
- Subió el dividendo a ~$0.73/trimestre (declarado 17 jun 2026).
- El precio subió ~12% (de ~$197.85 a $220.84), pero la tesis de compounder sigue intacta y más respaldada.
El modelo compounder
- Piezas pequeñas pero críticas: cada componente de IDEX es barato dentro de la máquina del cliente pero indispensable — poder de precio + clientes fieles + margen EBITDA ~26%.
- M&A disciplinado ('bolt-on'): reinvierte el efectivo comprando más líderes de nicho. El más grande reciente: Mott Corporation (filtración de metal poroso sinterizado, ~$1 mil millones, cerrado en septiembre de 2024, dentro de HST).
- Diversificación: toca decenas de mercados finales (agua, salud, ciencia, energía, bomberos), lo que suaviza los golpes de cualquier industria individual.
Dividendo (creciente, no de renta)
- ~$0.73 por acción al trimestre (subido en 2026; declarado 17 jun 2026, pagadero 24 jul 2026) → ~$2.92 anuales = ~1.3% a $220.84.
- 16 años consecutivos aumentándolo; pagado desde 1995. Modesto en rendimiento, pero es una máquina de subirlo cada año.
Liderazgo
- CEO: Eric Ashleman (desde diciembre de 2020; veterano de la casa, dirigió antes los segmentos FSDP y HST).
- Sede: Northbrook, Illinois. ~9,000 empleados; ~74.0 millones de acciones en circulación.
Anchor Fact
IDEX no fabrica un solo producto famoso: es dueña de decenas de pequeñas empresas que lideran nichos muy específicos —una bomba de precisión aquí, la pieza que mueve el líquido dentro de una máquina de análisis médico allá, las herramientas que usan los bomberos para rescatar gente—. Cada una es diminuta, pero juntas forman una máquina que crece comprando más piezas del rompecabezas y sube su dividendo 16 años seguidos.
Top 6 Risks
- Valuación premium — ~32x utilidad TTM, ~25x esperada; target promedio (~$238) solo ~8% arriba; no es una ganga
- Ciclicidad industrial — depende de que fábricas y clientes industriales sigan invirtiendo; se aplanó en 2023-2024 antes de esta recuperación
- Integración de M&A — el modelo depende de comprar y digerir bien; pagar de más (Mott a ~19x EBITDA) o fallar la integración rompe el compounding
- Muchos mercados finales — diversificación protege pero siempre hay un segmento débil; crecimiento orgánico de apenas 3-4%
- Dependencia del efectivo — menos combustible para el motor de adquisiciones si sube la deuda o las tasas
- No es dividendo de renta — ~1.3% no compensa si el crecimiento decepciona
Analyst Consensus
- Rating: Buy (~57% 'Strong Buy', ~29% 'Buy', ~14% 'Hold', 0% 'Sell')
- Target promedio: ~$237.71 (~+8% desde $220.84); rango $210-$260; 15 analistas
- Lectura honesta: upside promedio moderado y valuación exigente. Aquí no se compra un descuento — se compra un compounder de calidad y se reforzó porque la tesis se confirmó.
Tesis en una línea
Una máquina silenciosa de comprar-y-mejorar pequeños líderes de nicho: piezas invisibles pero críticas, márgenes altos, dividendo que sube 16 años seguidos — y un Q1 2026 récord que confirmó la recuperación y nos hizo reforzar la posición.
Research fecha: 9 Jul 2026 | Próxima revisión: Ene 2027
Esto no es asesoría financiera.
This is not financial advice. Consult a certified financial advisor.
The author may hold positions in the securities discussed.
Past performance does not guarantee future results.